10x Genomics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
10x Genomics wird ein jährliches Gewinn- und Umsatzwachstum von 1.5% bzw. 4.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 0.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -9.5% betragen.
Wichtige Informationen
1.5%
Wachstumsrate der Gewinne
0.60%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 17.5% |
| Wachstumsrate der Einnahmen | 4.9% |
| Zukünftige Eigenkapitalrendite | -9.49% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyse-Update • Apr 21
TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026
The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.Analyse-Update • Apr 06
TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook
Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.Seeking Alpha • Mar 24
10x Genomics: Undervalued Amid Consumables-Led Transition
Summary 10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting post-COVID instrument sales normalization and supporting recurring revenue expansion. TXG maintains a dominant 34% market share in single-cell biology, reinforced by increasing academic mindshare and strategic partnerships to drive future penetration. Operational efficiency initiatives, including OpEx cuts and consumable price reductions, position TXG to weather funding headwinds and margin pressures as the market stabilizes. Read the full article on Seeking Alpha
Analyse-Update • Mar 23
TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup
Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.
Analyse-Update • Mar 07
TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations
Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.Analyse-Update • Feb 21
TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment
The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.Analyse-Update • Feb 07
TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside
Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.Analyseartikel • Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...Analyse-Update • Jan 23
TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential
Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.Analyse-Update • Jan 08
TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment
Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.Analyse-Update • Dec 25
TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance
Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.Analyse-Update • Dec 11
TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook
Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.Analyse-Update • Nov 27
TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure
Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.Analyseartikel • Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...Analyse-Update • Nov 09
TXG: Institutional Interest And New Assay Expected To Influence Future Performance
Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.Analyse-Update • Aug 08
Advanced Genomics Tools Will Shape Future Precision Medicine
Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.Analyseartikel • Jun 20
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31%
10x Genomics, Inc. ( NASDAQ:TXG ) shares have had a really impressive month, gaining 31% after a shaky period...Analyseartikel • May 27
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package
Key Insights 10x Genomics' Annual General Meeting to take place on 3rd of June CEO Serge Saxonov's total compensation...Analyseartikel • May 14
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96
10x Genomics, Inc. ( NASDAQ:TXG ) just released its first-quarter report and things are looking bullish. 10x Genomics...Analyseartikel • Apr 11
Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump
Unfortunately for some shareholders, the 10x Genomics, Inc. ( NASDAQ:TXG ) share price has dived 29% in the last thirty...Analyseartikel • Mar 26
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Neue Analyse • Mar 23
Chan Zuckerberg Initiative Partnership Will Drive Future Demand
Strategic introduction of lower-priced products and sales reorganization are poised to drive volume growth and enhance market share in biopharma and academia.Analyseartikel • Feb 21
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
10x Genomics, Inc. ( NASDAQ:TXG ) shares have had a horrible month, losing 28% after a relatively good period...Seeking Alpha • Jan 06
10x Genomics: Struggling Amid Operational Challenges
Summary 10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's high price/cashflow ratio and declining share price raise concerns. Management's strategic investments in R&D and market expansion are promising, but operational inefficiencies and competition warrant a Sell rating for now. Read the full article on Seeking AlphaAnalyseartikel • Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Investors in 10x Genomics, Inc. ( NASDAQ:TXG ) had a good week, as its shares rose 3.5% to close at US$16.03 following...Seeking Alpha • Oct 12
10x Genomics: Deciphering The Preliminary Q3 Earnings
Summary 10x Genomics has faced significant revenue declines and operational challenges, with Q3 revenue missing expectations and instrument sales dropping 46% year-over-year. Despite the setbacks, consumables and services revenue showed growth, indicating customer retention and continued use of 10x's platforms. The company is undergoing commercial process adjustments and remains confident in its long-term growth prospects, despite current economic pressures and competition. I remain cautious about initiating a TXG position immediately but see potential buying opportunities if the stock shows signs of recovery and stability. Read the full article on Seeking AlphaAnalyseartikel • Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 03
10x Genomics Is Still A Long Way From Profitability
Summary 10x Genomics has impressive financials but isn't expected to be profitable until at least 2028, posing significant investment risks. The company's growth heavily relies on its Chromium platform, with future growth dependent on the acceptance of its newer platforms, Xenium and Visium. Despite revenue growth, declining gross margins and increasing operating losses raise concerns about the company's ability to reach profitability without incurring debt or diluting shares. Given the long timeline to profitability and potential financial challenges, I recommend selling TXG and caution current investors to monitor gross margins closely. Read the full article on Seeking AlphaAnalyseartikel • Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Those holding 10x Genomics, Inc. ( NASDAQ:TXG ) shares would be relieved that the share price has rebounded 30% in the...Seeking Alpha • Jul 10
10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Summary 10x Genomics' share price is down nearly 15% today and >70% year-to-date. The company offers innovative products for biological analysis but faces heavy losses and declining revenues of key products. The acquisition of Fluent Biosciences by Illumina, announced yesterday, poses a threat to 10x's key revenue driver, Chromium single cell platform. Bruker Corporation has rescued another key rival, Nanostring, which has recently won an important court victory against 10x relating to patents. In a very tricky industry characterized by multiple failures — witness Pacific Bio — 10x's current valuation of nearly $2bn faces further erosion, in my view, with positives on the horizon. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 709 | -60 | 25 | 34 | 9 |
| 12/31/2027 | 659 | -91 | -8 | 20 | 15 |
| 12/31/2026 | 613 | -120 | -36 | 42 | 15 |
| 12/31/2025 | 643 | -44 | 130 | 136 | N/A |
| 9/30/2025 | 642 | -76 | 82 | 89 | N/A |
| 6/30/2025 | 644 | -85 | 57 | 67 | N/A |
| 3/31/2025 | 625 | -157 | 44 | 57 | N/A |
| 12/31/2024 | 611 | -183 | -7 | 7 | N/A |
| 9/30/2024 | 630 | -183 | 25 | 39 | N/A |
| 6/30/2024 | 632 | -240 | -33 | -8 | N/A |
| 3/31/2024 | 625 | -264 | -74 | -27 | N/A |
| 12/31/2023 | 619 | -255 | -65 | -15 | N/A |
| 9/30/2023 | 591 | -223 | -113 | -27 | N/A |
| 6/30/2023 | 568 | -172 | -118 | -11 | N/A |
| 3/31/2023 | 536 | -174 | -126 | -17 | N/A |
| 12/31/2022 | 516 | -166 | -165 | -34 | N/A |
| 9/30/2022 | 504 | -167 | -161 | -42 | N/A |
| 6/30/2022 | 498 | -142 | -161 | -58 | N/A |
| 3/31/2022 | 499 | -89 | -129 | -38 | N/A |
| 12/31/2021 | 490 | -58 | -123 | -21 | N/A |
| 9/30/2021 | 459 | -455 | -253 | -157 | N/A |
| 6/30/2021 | 406 | -504 | -264 | -187 | N/A |
| 3/31/2021 | 333 | -533 | -289 | -219 | N/A |
| 12/31/2020 | 299 | -543 | -256 | -218 | N/A |
| 9/30/2020 | 262 | -134 | -104 | -81 | N/A |
| 6/30/2020 | 251 | -78 | -46 | -11 | N/A |
| 3/31/2020 | 264 | -49 | -19 | 23 | N/A |
| 12/31/2019 | 246 | -31 | -8 | 35 | N/A |
| 9/30/2019 | 221 | -100 | N/A | -23 | N/A |
| 6/30/2019 | 197 | -105 | N/A | -43 | N/A |
| 3/31/2019 | 170 | -105 | N/A | -57 | N/A |
| 12/31/2018 | 146 | -112 | N/A | -76 | N/A |
| 12/31/2017 | 71 | -19 | N/A | -11 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TXG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: TXG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: TXG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: TXGDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.5% pro Jahr).
Hohe Wachstumseinnahmen: TXGDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: TXG wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/07 13:50 |
| Aktienkurs zum Tagesende | 2026/05/07 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
10x Genomics, Inc. wird von 22 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |